Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial...
Scribe Therapeutics (NASDAQ: SCTX) has filed for an initial public offering of 7.15 million shares priced between $13.00 and $15.00 per share, targeting gross proceeds of approximately $100.1 million at the midpoint of the range. At a midpoint price of $14.00, Scribe would debut with an implied market capitalization of approximately $226.5 million based on 16.18 million shares outstanding following the offering and concurrent private placement. The IPO is being led by Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities.
Founded by Nobel Prize-winning CRISPR pioneer Dr. Jennifer Doudna, alongside CEO Dr. Benjamin Oakes and a team of leading gene-editing scientists, Scribe Therapeutics is developing a new generation of in vivo CRISPR-based genetic medicines aimed at treating some of the world's most common cardiovascular and metabolic diseases. Rather than focusing solely on rare genetic disorders, the company is engineering therapies for large patient populations suffering from elevated cholesterol, lipoprotein(a), and triglycerides using its proprietary "CRISPR by Design" platform, which integrates artificial intelligence, machine learning, and large-scale experimental validation to optimize gene-editing performance.
Scribe's lead product candidate, STX-1150, utilizes the company's proprietary ELXR epigenetic silencing technology to suppress the PCSK9 gene responsible for elevated LDL cholesterol without permanently altering the underlying DNA sequence. Unlike traditional CRISPR editing approaches that permanently modify genes, ELXR is designed to provide durable cholesterol reduction through reversible epigenetic regulation, potentially offering an improved safety profile while maintaining long-lasting therapeutic benefit. The company recently initiated its first-in-human clinical trial in Australia after receiving regulatory clearance, with initial safety, tolerability, and LDL cholesterol reduction data expected during the first half of 2027.
Beyond STX-1150, Scribe is advancing two additional wholly owned cardiovascular programs. STX-1200 targets elevated lipoprotein(a) (Lp(a)), while STX-1400 targets APOC3 to reduce triglycerides. Both candidates utilize the company's proprietary XE gene-editing platform and have demonstrated encouraging preclinical data, including durable target suppression and no detectable off-target editing across extensive safety analyses. Together, the three programs position Scribe to address several of the largest remaining unmet needs in cardiovascular medicine.
The company's technology has also attracted validation from several of the world's largest pharmaceutical companies. Sanofi has agreed to purchase approximately $7.5 million of common stock through a concurrent private placement, while Eli Lilly has indicated interest in purchasing additional shares in the IPO that could increase its ownership to as much as 10.9% following the offering. Scribe has also generated more than $180 million in collaboration payments, milestones, and research funding through strategic partnerships with Sanofi and Lilly, providing meaningful non-dilutive capital while advancing additional CRISPR programs outside its wholly owned pipeline.
Financially, Scribe remains a clinical-stage biotechnology company with no commercial products. Collaboration revenue increased to $51.2 million in 2025 from $27.4 million in 2024, reflecting progress under its pharmaceutical partnerships, while the company's net loss improved to $21.8 million from $47.8 million over the same period. Management reported approximately $43.0 million in preliminary cash, cash equivalents, and short-term investments as of June 30, 2026, prior to the IPO. Net proceeds from the offering are expected to fund continued clinical development of STX-1150, advancement of STX-1200 and STX-1400, expansion of the company's CRISPR technology platform, and general corporate purposes.
Scribe Therapeutics enters the public markets as one of the more differentiated companies in the gene-editing sector. By focusing on common cardiovascular diseases rather than rare disorders and developing technologies designed to deliver durable therapeutic effects without permanent genetic modification, the company is attempting to expand CRISPR's commercial opportunity into significantly larger patient populations. While clinical execution remains the primary risk, Scribe's combination of a proprietary technology platform, high-profile scientific founders, strategic pharmaceutical partnerships, and multiple wholly owned cardiovascular programs positions it as an IPO that gene-editing and biotechnology investors will likely watch closely.
Scribe Therapeutics will make it's Nasdaq debut on Friday, July 24th.
